DOCSLIB.ORG

Camurus Is Providing the Following Cautionary Statement

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Camurus Is Providing the Following Cautionary Statement Company presentation Jefferies 2019 Healthcare Conference June 4, 2019 New York, NY Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Camurus value drivers • In-house developed with strong IP Unique FluidCrystal® • New generation long-acting depot technology nanotechnologies • Validated in 20 clinical trials and by approved products Broad, late-stage • 10 clinical programs in addiction, pain, oncology, R&D pipeline endocrinology, obesity and CV Approved • Weekly and monthly Buvidal® approved in the EU commercial products and Australia for treatment of opioid dependence Listed on Nasdaq STO; ticker CAMX Market Cap: ~ USD 350 million ® Own commercial • Fully operational for Buvidal launches in Europe Cash position: ~ USD 43 million (Q1 ‘19) and Australia organization Employees: 115 • Braeburn Pharmaceuticals, Rhythm, Solasia Pharma, HQ: Lund, Sweden Partnerships Medison… Regional Offices: Cambridge, Mannheim, Paris, Sydney Experienced management and dedicated teams 3 Recent highlights EU and Australian approvals of Buvidal® , weekly and monthly SC EU and Australian launch of buprenorphine depots, for the treatment of opioid dependence Buvidal® in opioid dependence US tentative approval of Brixadi™ for opioid use disorder • Initiated in the Nordics, Braeburn initiated court proceedings to overturn US market Germany and the UK exclusivity and seek immediate market approval of Brixadi™ • Positive market signals Expansion of the evidence base for Buvidal® with DEBUT and UNLOC-T clinical studies in out-patient and criminal justice settings • Launch being expanded in the EU and Australia with pricing Publication of Phase 3 long-term safety results in Addiction and reimbursement approvals Positive Phase 3 results for CAM2038 in chronic pain • Fully operational commercial Phase 3 readiness for CAM2029, octreotide SC depot, in teams in all market acromegaly Rights issue of USD 42 million in gross proceeds • Effective product distribution 4 FluidCrystal® in situ gel formation Easy to administer Good safety and tolerability profile Rapid onset & long-acting release Unique mixtures of endogenous lipids Applicable across substance classes Strong intellectual properties INJECTION WATER ABSORPTION DRUG RELEASE +400 PATENTS & APPLICATIONS >2000 SUBJECTS HAVE RECEIVED >20,000 INJECTIONS IN LIQUID DRUG PRODUCT SOLVENT RELEASE DEPOT BIODEGRADATION TO LIQUID CRYSTAL (LC) FORMULATION BEFORE INJECTION: COMPLETE RESOLUTION >20 CLINICAL TRIALS SPC+GDO+SOLVENT+DRUG SECONDS HOURS WEEKS / MONTHS 5 Tiberg F, Johnsson M, Jankunec M et al., Chemistry Letters 2012; 41(10): 1090-1092; Tiberg F, Johnsson M., J. Drug Delivery Science Techn. 2011; 21 (1): 101-1 FluidCrystal – Long-acting peptide release Immediate release pasireotide (Signifor®) Pasireotide FluidCrystal® (CAM4071) 10 10 Pasireotide IR 600 ug Pasireotide FluidCrystal 20 (SC thigh, n = 94) mg (SC thigh, n = 12) 1 1 pasireotide plasma concentrationpasireotide plasma (ng/mL) concentrationpasireotide plasma (ng/mL) 0.1 0.1 0 7 14 21 28 0 7 14 21 28 Time (days) Time (days) Single dose injection at t=0; clinical Phase 1 data, mean values. Tiberg, F. et al, Poster presentation at ECE, Barcelona, May 2018 6 Weekly and monthly buprenorphine depots Illustration of population pharmacokinetic profiles for Buvidal vs sublingual buprenorphine Weekly Buvidal vs. Daily sublingual buprenorphine Weekly vs. Monthly Buvidal Population PK analysis and modelling based on data from four clinical studies (N=236). Diagnostic testing demonstrated predictive buprenorphine concentrations and good agreement between observed and predicted data percentiles. Steady state data. Sources: Abstract presented at the Annual conference of the Society for the Study of Addiction- November 2018; Albayaty M, Linden M, Olsson H, Johnsson M, Strandgarden K, Tiberg F. Adv Ther. 2017;34(2):560–575. 7 Clinically documented compounds + FluidCrystal® technology 8 Advancing product pipeline PRODUCT PHASE 1-2 PHASE 3 REGISTRATION MARKET Buvidal® q1w OPIOID DEPENDENCE MARKET Buvidal® q4w OPIOID DEPENDENCE MARKET Brixadi® q1w OPIOID DEPENDENCE - BRAEBURN1 TENTATIVE APPROVAL Brixadi® q4w OPIOID DEPENDENCE - BRAEBURN1 TENTATIVE APPROVAL CAM2038 q1w CHRONIC PAIN1 PHASE 3 CAM2038 q4w CHRONIC PAIN1 PHASE 3 CAM2029 ACROMEGALY PHASE 1-2 CAM2029 NEUROENDOCRINE TUMORS PHASE 1-2 CAM2032 PROSTATE CANCER PHASE 1-2 CAM4072 GENETIC OBESITY DISORDERS - RHYTHM2 PHASE 1-2 CAM2043 PULMONARY ARTERIAL HYPERTENSION PHASE 1-2 CAM2047 CINV3 PHASE 1-2 CAM2048/58 POSTOPERATIVE PAIN & PONV4 - BRAEBURN1 PHASE 1-2 1. Braeburn holds the rights to North America; 2. Developed by Rhythm Pharmaceuticals under a worldwide license to FluidCrystal®; 3. Chemotherapy-induced nausea and vomiting; 4. Postoperative nausea and vomiting; 9 Buvidal®/Brixadi™ Weekly and monthly buprenorphine depots Game-changer in opioid dependence treatment Opioid dependence – escalating global health crisis Mounting US opioid overdose deaths2 (thousands) • Largest society burden of all drugs1 70 From other drugs 60 • 34 million opioid users worldwide1 Opioid overdose 50 • High need for better access to care 40 and new treatment alternatives 30 • Investment in treatment brings substantial 20 value and saves lives 10 • Significant limitation with current daily 0 medications 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 #1 cause of death for people under 50 in the US 30:1 non-fatal to fatal overdoses3 Recent US life expectancy decline largely 4 Source: 1. UNODC, World Drug Report 2017; 2. Center for Disease Control & Prevention 2018; 3. Frazier at al, 2017, Journal of due to opioids the American Medical Association; 4. Crow D. Financial Times.com, accessed on March 13, 2018, https://www.ft.com/content/d22e742c-e65c-11e7-97e2-916d4fbac0da 11 Buvidal® – first long-acting injection treatment of opioid dependence in the EU and Australia • Buvidal® is indicated (EU) for treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents from 16 years • Individualized dosing for use across treatment phases: initiation, switching from daily medications and long-term maintenance treatment • Superiority versus daily standard treatment with daily buprenorphine/naloxone included in clinical outcomes • Removes burdens and stigma of daily medication • HCP administration safeguards against diversion, misuse and pediatric exposure Source: Buvidal Summary of Product Characteristics (SmPC), 2018 12 INTERNAL USE ONLY. NOT TO BE CONSIDERED BRIEFING MATERIAL FOR REPRESENTATIVES. Buvidal brings unique values to patients and HCPs CHOICE OF ROOM CLIN. DATA WEEKLY MONTHLY MULTIPLE SMALL LOW DAY ONE PRODUCT INJECTION TEMP. VS ACTIVE DOSING DOSING DOSES NEEDLE VOLUMES INITIATION SITES STORAGE CONTROL* * 23G 0.16 – 0.64 mL – – – 19G– 0.5 ––1.5 mL – – – – – – –20G 3.4– mL – – – *Based on product label information. 13 ® Strong clinical data for Buvidal Key publications versus daily standard treatment Non-inferior and Superior efficacy demonstrated in pivotal Phase 3 study versus standard daily SL BPN/NX1 High Treatment Retention ~70% at 48 weeks2 Blockade of Opioid Effects from the first dose3 Effective suppression of withdrawal and cravings1,2,3 Safety Profile comparable to SL BPN/NX except for mild and moderate injection site reactions1,2 No Opioid Overdoses reported across clinical studies for participants treated with Buvidal®1,2,3,4,5 High Patient Satisfaction including versus SL BPN2 1Lofwall et al. JAMA Int. Med. 2018;178(6); 764-773; 2Frost et al, Addiction, 2019 in press, 3Walsh et al, JAMA Psychiatry 4 5 2017;74(9):894-902; Haasen, C, et al, J Subst Abuse Treat. 2017;78:22-29; Albayaty M, et al, Adv Ther. 2017 34(2):560-575; 14 6SL BPN sublingual buprenorphine/naloxone High satisfaction amongst patients “CAM2038 compared to my previously prescribed sublingual buprenorphine treatment” 83% Much better Features rated as extremely important POSITIVE or much better (7 on scale 1-7) by Slightly better majority of patients Spares regular visits to the pharmacy About the same N=133 Prevents others access to my medication Prevents accidental exposure to children Daily medication not required Slightly worse Improves my privacy as a patient Helps me not miss or skip medication dose Much worse Allowed to travel with no medication 15 Source: Poster presentation ASAM 2018. Phase 3 Long-Term Safety Study HS-14-499,
Load more

Recommended publications
  • CAM2038 Weekly Opioid Dependence
    Cowen & Co. Annual Health Care Conference 2017 Camurus Advancing late stage pipeline with high market potential Company Presentation, 7 March 2017 Forward-looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Camurus overview LISTED ON NASDAQ STOCKHOLM • Innovation that delivers 3rd DEC, 2015 − Proprietary FluidCrystal® technology used in 10 clinical programs − Preclinical to NDA/MAA enabling MARKET CAP pipeline programs − Expansive and rewarding pharma partnerships
    [Show full text]
  • Camurus Company Presentation
    Corporate presentation Updated 15 July 2021 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 3 Long-acting medications addressing key healthcare challenges 4 Camurus snapshot Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in addiction, • Fully operational infrastructure in Europe pain, endocrine disorders and oncology and Australia • Three Phase 3 programs • Buvidal® to date available in
    [Show full text]
  • Company Presentation
    Company presentation November 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in • Fully operational infrastructure in Europe addiction, pain, oncology, endocrine and Australia disorders and CV diseases • Buvidal® to date launched in 9 countries • Two ongoing
    [Show full text]
  • Camurus Company Presentation Cowen 2020
    Company Presentation Cowen & Co. 40th Annual Health Care Conference 2 March 2020, Boston, MA Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 LISTED ON NASDAQ STO; TICKER CAMX MARKET CAP Camurus in brief ~ SEK 4.5 billion EMPLOYEES: 130 HQ: Lund, Sweden REG. OFFICES: Cambridge, Mannheim, Sydney, Paris ® Unique FluidCrystal Two Phase 3 programs nanotechnologies • Late-stage pipeline with 10 innovative • In-house developed with strong IP clinical
    [Show full text]
  • Invitation to Subscribe for Shares in Camurus AB
    Invitation to subscribe for shares in Camurus AB Please note that the subscription rights are expected to have an economic value. In order to not lose the value of the subscription rights, holders must either: • Exercise the subscription rights received and subscribe for new shares no later than 25 March 2019, or • Sell the subscription rights received, but not exercised, no later than 21 March 2019. Please note that shareholders with nominee-registered shareholdings subscribe for new shares through their custodian/nominee. The distribution of this prospectus and the subscription for new shares are subject to restrictions in certain jurisdictions (see “Selling and transfer restrictions”). FINANCIAL ADVISORS IMPORTANT INFORMATION For certain definitions used in this prospectus, see “Certain definitions” on the next page. A Swedish version of this prospectus has been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”) in accordance with Chapter 2, sections 25 and 26 of the Swedish Financial Instruments Trading Act (lagen (1991:980) om handel med finansiella instrument). Approval and registration does not imply that the SFSA guarantees that the information in the prospectus is accurate or complete. The prospectus and the offering hereunder are governed by Swedish law. Disputes arising in connection with this prospectus, the offering and related legal matters shall be settled exclusively by Swedish courts. The prospectus has been prepared in both Swedish and English language versions. In the event of any conflict between the versions, the Swedish version shall prevail. Camurus has not taken, and will not take any actions to allow a public offering in any jurisdiction other than Sweden.
    [Show full text]
  • Camurus Had an Excellent Start of 2021 with Strong Revenue Growth, New Regulatory Approvals and Progress in the Pipeline”
    INTERIM REPORT FOR THE FIRST QUARTER 2021 “Camurus had an excellent start of 2021 with strong revenue growth, new regulatory approvals and progress in the pipeline” Camurus is an international science-led biopharmaceutical company committed to developing and commercializing innovative medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the unique proprietary FluidCrystal® drug delivery technologies and its extensive R&D and sales expertise. Camurus’ clinical pipeline includes product candidates for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus’ share is listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com First quarter summary Q1 • Total revenue amounted to SEK 126 (49) million, an increase of 155% (161% at CER1) • Product sales were SEK 124 (49) million, an increase of 156% (162% at CER) • Sales growth was 20% (18% at CER) compared to the previous quarter Total revenue • Market approval for Buvidal in New Zealand SEK 126 million • CHMP recommended approval of a new 160mg dose of Buvidal in the EU +155% • Buvidal launched in Spain and the first hundred patients received treatment • Positive decision from health economic evaluation of Buvidal by Haute Autorité de Santé in France Product sales • FDA issued Safe to Proceed letter for the start of a Phase 3 study of CAM2029 for the treatment of SEK 124 million neuroendocrine tumors +156% • Scientific advice with FDA regarding the clinical program for CAM2029 for polycystic liver disease • New patent issued for CAM2038 Weekly in the US with patent term until July 2032 Operating result • The financial outlook for 2021 is unchanged; total revenue SEK 680 – 750 million2, SEK -26 million whereof product sales SEK 620 – 680 million, and the operating result SEK -120 – 0 million2 +66% 1) At constant exchange rates in January 2021.
    [Show full text]
  • Solasia Acquires Exclusive License and Distribution Rights from Camurus for Episil® Oral Liquid in Japan and China
    Camurus AB Press release Ideon Science Park SE-223 70 Lund, Sweden www.camurus.com Phone: +46 46 286 57 30 Solasia acquires exclusive license and distribution rights from Camurus for episil® oral liquid in Japan and China Lund, Sweden, and Tokyo, Japan — March 30, 2015 — Camurus AB (“Camurus”) and Solasia Pharma K.K. (“Solasia”) jointly announced today that they have entered into a license and distribution agreement for episil® oral liquid, a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of some cancer therapies, as well as other oral lesions. As part of the agreement Solasia receives exclusive commercialization rights to episil® in Japan and China, where it has ongoing operations and is building a specialty pharmaceutical infrastructure in the area of oncology and cancer supportive care. Solasia plans to first launch episil® in China followed by Japan. “We are pleased to enter into this collaboration with Camurus, and for the opportunity to commercialize episil® in Japan and China” said Yoshihiro Arai, President and Representative Director of Solasia. “Solasia specializes in innovative oncology treatments, and episil® will take its place as one of the core products in our oncology pipeline”, he continued, noting that episil® fills an important unmet need in daily pain management associated with cancer care, and will contribute to improved quality of life for cancer patients in Japan and China. “The new partnership with Solasia expands Camurus’ distributor network for episil® oral liquid in two of the key markets in Asia”, said Fredrik Tiberg, President and CEO of Camurus.
    [Show full text]
  • Pipeline Progress
    Second quarter results 2020 Audiocast presentation 16 July 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 3 Agenda • Second quarter 2020 overview Company participants • Buvidal progress in EU & Australia Fredrik Tiberg, PhD President & CEO, Head R&D • Pipeline update • Key take-aways Eva Pinotti Lindqvist • Revised Outlook 2020 Chief Financial Officer • Q&A Richard Jameson Chief Commercial Officer 4 Continued strong performance in the second
    [Show full text]
  • Fourth Quarter & Full Year Results 2019
    Fourth quarter & full year results 2019 12 February 2020 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements 2 Agenda • Fourth quarter 2019 overview Participants • Buvidal progress in EU & Australia Fredrik Tiberg, PhD • US approval and launch status President & CEO, Head R&D • R&D pipeline update • Key take-aways Eva Pinotti Lindqvist Chief Financial Officer • Q&A 3 Financial overview Financials Q4 2019 FY 2019 2019 Product sales 2020 Guidance FY 2020 MSEK MSEK MSEK 80 72.1 *) Net revenue 35.0 (7.8) 105.6 (49.3) 70 Total revenues 290 – 330 60 – product sales 240 – 280 – product sales 30.3 (5.1) 72.1 (11.3) 50 41.9 OPEX 570 – 610 Operating 40 result -88.4 (-103.2) -360.0 (-287.2) MSEK *) 30 excl.
    [Show full text]
  • Brixadi™In the US
    Company presentation July 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • 10 innovative clinical programs in • Fully operational commercial addiction, pain, oncology, endocrine infrastructure in Europe and Australia disorders and CV diseases • Buvidal® to date launched in 8 countries • Two
    [Show full text]
  • Covid-19 Causing Spike in Opioid Overdoses
    Company presentation November 2020 2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus‘ ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases. Camurus undertakes no obligation to update forward-looking statements Long-acting medications addressing key healthcare challenges 4 Corporate highlights Rapidly growing commercial Broad late-stage pipeline stage company • +10 innovative clinical programs in • Fully operational infrastructure in Europe addiction, pain, oncology, endocrine and Australia disorders and CV diseases • Buvidal® to date launched in 10 countries • Two ongoing
    [Show full text]
  • Annual Report 2015 Contents This Is Camurus
    INNOVATIVE NANOSCALE THERAPEUTICS ANNUAL REPORT 2015 CONTENTS THIS IS CAMURUS This is Camurus ................................................................................................ 1 Leading innovation Key performance indicators ............................................................. 2 • FluidCrystal® – award-winning drug delivery technology 2015 In brief ......................................................................................................... 3 • Broad and advanced product pipeline Statement from the CEO ...................................................................... 4 • More than 400 patents and patent applications Operating environment........................................................................ 6 Strategy..................................................................................................................... 7 The patient in focus Technology platforms ..........................................................................10 • Simple and flexible administration Our development portfolio ..........................................................14 • Long-acting formulations for improved compliance Marketing organisation ......................................................................18 • Improved treatment outcomes and quality of life Employee portraits ..................................................................................20 Our development portfolio, cont. .........................................21 Strategic partnerships Early R&D projects ....................................................................................26
    [Show full text]